SCHEMBL7150949

SCHEMBL7150949

Fc1ccc(-c2csc(Nc3cc(Cl)cc(Cl)c3)n2)c(F)c1.Oc1cccc(Nc2nc(-c3ccc(C(F)(F)F)cc3)cs2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 2/20 0.69
ALOX5 P09917 8/20 0.59
VCP P55072 1/20 0.56
CYP1A2 P05177 3/20 0.48
CYP1A1 P04798 2/20 0.48
CYP1B1 Q16678 2/20 0.48
MAPT P10636 4/20 0.47
KDM4E B2RXH2 3/20 0.47
MAPK1 P28482 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CFTR P13569 1/20 0.45
NPC1 O15118 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
PKM P14618 1/20 0.45
CYP2C19 P33261 1/20 0.45
CLK1 P49759 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16603960 0.83 AGER (1.00) AGERALOX5VCPCYP1A2CYP1A1
SCHEMBL7115473 0.83 ALOX5 (0.73) AGERALOX5VCPCYP1A2MAPT
SCHEMBL7113308 0.80 CYP1B1 (0.67) AGERALOX5VCPCYP1A2CYP1A1
SCHEMBL7246864 0.80 ALOX5 (0.79) ALOX5VCPCYP1A2CYP1A1CYP1B1
SCHEMBL28908960 0.78 AGER (0.62) AGERALOX5VCPMAPTMEN1
SCHEMBL7114964 0.76 ALOX5 (1.00) ALOX5VCPCYP1A2MAPTMAPK1
SCHEMBL7115739 0.75 ALOX5 (0.81) ALOX5VCPCYP1A2CYP1A1CYP1B1
SCHEMBL7263150 0.74 VCP (0.80) ALOX5VCPCYP1A2CYP1A1CYP1B1
SCHEMBL23553570 0.73 VCP (1.00) ALOX5VCPMAPTKDM4EMAPK1
SCHEMBL7153995 0.73 ALOX5 (0.62) ALOX5VCPCYP1A2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220380-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-11-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220380-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 AGER 439/4885ALOX5 2040/4885VCP 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.